The exon-skipping oligonucleotide, kitstop, depletes tissue-resident mast cells in vivo to ameliorate anaphylaxis

HIGHLIGHTS

• who: Barry A. Hedgespeth et al. from the Kyoto Pharmaceutical University, Japan have published the paper: The exon-skipping oligonucleotide, KitStop, depletes tissue-resident mast cells in vivo to ameliorate anaphylaxis, in the Journal: (JOURNAL)
• what: COPYRIGHT This is an open-access article use distribution or reproduction in other forums is permitted provided original author(s) and copyright owner(s) are credited and that original publication in this journal is cited in accordance with accepted academic practice. The authors report the use of an exon-skipping oligonucleotide, which the authors have previously termed KitStop, to . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.